- Donafenib
-
- $84.00 / 1mg
-
2025-07-24
- CAS:1130115-44-4
- Min. Order:
- Purity: 99.88%
- Supply Ability: 10g
|
| | Donafenib Basic information |
| | Donafenib Chemical Properties |
| Melting point | 202-204?C | | storage temp. | -20°C Freezer | | solubility | DMSO: soluble; Methanol: soluble | | form | A solid | | color | White to off-white | | InChI | InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31) | | InChIKey | MLDQJTXFUGDVEO-UHFFFAOYSA-N | | SMILES | c1(Cl)ccc(NC(Nc2ccc(Oc3ccnc(C(=O)NC)c3)cc2)=O)cc1C(F)(F)F |
| | Donafenib Usage And Synthesis |
| Mechanism of action | Donafenib blocks the proliferation of tumor cells by inhibiting Raf kinase and VEGFR tyrosine kinase. The deuterated methyl group in donafenib improves the metabolic stability of the drug, resulting in a prolonged half-life, reduced systemic clearance, and increased systemic exposure. Donafenib has shown significantly improved overall survival compared to sorafenib in the treatment of patients with unresectable HCC, while having a favorable safety and tolerability profile. | | Chemical Properties | Off-White to Light Pink Solid | | Uses | Labelled Sorafenib, a potent RAF kinase inhibitor. Antineoplastic. | | Synthesis | The synthetic route began with the amidation of methyl formate 31.2 using chloromethane-d3-amine (31.1) as a deuterium source to afford CD3-amide 31.3 in high yield (98%). Aminophenol 31.4 was reacted with 31.2 in dimethyl sulfoxide via a SNAr displacement reaction to afford diaryl ether 31.5. Finally, aniline was reacted with isocyanate 31.6 to synthesize donafenib (31) from 31.3 in 79% yield.
 |
| | Donafenib Preparation Products And Raw materials |
|